Jump Trading, a major global trading firm, is moving deeper into prediction markets. According to reports, the company is acquiring minority stakes in PolymarketJump Trading, a major global trading firm, is moving deeper into prediction markets. According to reports, the company is acquiring minority stakes in Polymarket

Jump Trading Invests in Prediction Markets Polymarket and Kalshi

2026/02/10 14:25
2 min read

Jump Trading, a major global trading firm, is moving deeper into prediction markets. According to reports, the company is acquiring minority stakes in Polymarket and Kalshi. In return, Jump will provide market-making and liquidity services to both platforms.

This move shows the growing interest from traditional finance in event-based trading. Prediction markets have seen strong growth, especially around elections and major global events.

A Different Kind of Investment Deal

Jump Trading is not investing cash in the usual way. Instead, it is offering liquidity to improve trading conditions. Kalshi will give Jump a fixed equity stake. Polymarket’s equity share will grow based on how much trading volume Jump helps to make.

This setup benefits both sides, as Jump earns ownership by supporting active markets. While the platforms gain better pricing, smoother trades and less volatility.

Why Liquidity Matters in Prediction Markets

Prediction markets depend on fast and accurate price movement. Without enough liquidity, odds can swing sharply, and this can scare away serious traders.

Jump Trading specializes in high-frequency trading. Its systems can place large volumes of trades quickly. This helps narrow spreads and keep prices stable. For users, this means better odds and fairer markets.

Regulated Kalshi vs Crypto-Based Polymarket

Kalshi operates under US regulation. It is approved by the Commodity Futures Trading Commission. This makes it attractive to institutions and professional traders who need legal clarity.

Moreover, Polymarket runs on blockchain technology. It has grown rapidly but is not available to US users due to restrictions. Many US traders still access it using VPNs. Jump’s involvement may help reduce sharp price swings on the platform.

Prediction Markets Are Growing Fast

Prediction market activity surged in 2024. Volumes across platforms passed $3 billion, driven mainly by election-related trading. Users increasingly see these markets as tools to track real-world outcomes.

By backing both Kalshi and Polymarket, Jump Trading is covering both sides of the market. One is regulated and traditional while the other is decentralized and crypto-native.

A Strong Signal From Traditional Finance

Jump Trading’s move shows that prediction markets are gaining serious attention. These platforms are no longer niche experiments, and are becoming part of the broader trading ecosystem.

As demand grows, more institutional players may follow. Liquidity, regulation and trust will likely shape which platforms lead the next phase of growth.

The post Jump Trading Invests in Prediction Markets Polymarket and Kalshi appeared first on Coinfomania.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.08358
$0.08358$0.08358
-0.95%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26